Adaptive Biotechnologies Reports Strong Q3 2025 Growth

Adaptive Biotechnologies ( (ADPT) ) has released its Q3 earnings. Here is a breakdown of the information Adaptive Biotechnologies presented to its investors.

Adaptive Biotechnologies, a commercial-stage biotechnology company, focuses on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases, primarily operating in the biotechnology sector with a unique approach to immune-driven diagnostics and therapeutics.

In its third quarter of 2025, Adaptive Biotechnologies reported strong financial growth, driven by the profitability and cash flow positivity of its Minimal Residual Disease (MRD) business. The company highlighted significant progress in its MRD and Immune Medicine programs, positioning itself for sustained growth.

Key financial metrics for the quarter included a revenue of $94.0 million, marking a 102% increase from the previous year, with the MRD business contributing 60% of this revenue and achieving a 52% growth. The company also reported a net income of $9.5 million, a significant turnaround from a net loss in the previous year. The clonoSEQ test volume increased by 38%, and the company raised its full-year MRD revenue guidance to $202-$207 million.

Operating expenses rose slightly by 6% to $83.7 million, while the company achieved an Adjusted EBITDA of $28.0 million, compared to a loss in the previous year. Excluding revenue from a terminated agreement with Genentech, the company still showed a notable improvement in financial performance.

Looking ahead, Adaptive Biotechnologies remains optimistic about its growth trajectory, with updated financial guidance indicating a focus on reducing operating expenses and cash burn while continuing to expand its MRD business. The company’s strategic initiatives and disciplined execution are expected to drive long-term value creation.